1801 Augustine Cut-Off
About Incyte Corporation
Drug Discovery & Development
Since we began our drug-discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.
Incyte has an exceptional team of drug discovery and development scientists led by distinguished executives with proven records of success and many scientific and clinical achievements. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success. We have a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations. Our therapeutic focus is primarily on oncology.
One Molecule at a Time
439 articles with Incyte Corporation
The MPN community is encouraged to participate in awareness initiatives and access new resources at VoicesofMPN.com.
Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019
The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.
Incyte Corporation announced that it will present at the following investor conferences during the month of March:
Two of the three drugs that were up for review in mid- to late-February received much earlier approval in December 21, the day before the federal government shutdown. The shutdown ended on January 25, 2019.
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company’s development portfolio.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 14, 2019.
Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease
Incyte Corporation today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD).
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January
Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
Updated data to be presented today at the 60th annual ASH meeting
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.
Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs
Total product-related revenues of $430 million for the three months and $1.2 billion for the nine months ended September 30, 2018; Jakafi® (ruxolitinib) revenues of $348 million in 3Q 2018 and $1.0 billion YTD 2018
Incyte Corporation announced today that it has been named one of the global biotechnology and pharmaceutical industry’s top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication’s annual Top Employer’s Survey.
10/24/2018Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday.
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
Updated results presented at ESMO support planned submission of NDA in U.S. in 2019
ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Integrated safety analysis reflects long-term results from 3,492 treated patients for 7,860 patient-years of exposure
Incyte Corporation announced today that it has scheduled its third quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 30, 2018.
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
Study met primary and key secondary endpoints, demonstrating significant improvement from baseline in EASI score and reduced itch compared to vehicle